StockData
Cognition Therapeutics Inc logo

Cognition Therapeutics Inc (CGTX) stock

CGTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30
$0.60−0.03 (-4.75%)

Close on Nov 18, 2026Market cap $57.06MP/E –Yield –

Cognition Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Cognition Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$17.68M. For fiscal 2025 it was -$24.59M. The highest annual figure on record is -$3.43M in fiscal 2020.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$24.59M–
FY2024Dec 31, 2024-$28.47M–
FY2023Dec 31, 2023-$16.02M–
FY2022Dec 31, 2022-$18.53M–
FY2021Dec 31, 2021-$3.63M–
FY2020Dec 31, 2020-$3.43M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$3.05M–
Q1 FY2026Mar 31, 2026-$5.54M–
Q4 FY2025Dec 31, 2025-$3.44M–
Q3 FY2025Sep 30, 2025-$5.65M–
Q2 FY2025Jun 30, 2025-$5.62M–
Q1 FY2025Mar 31, 2025-$9.88M–
Q4 FY2024Dec 31, 2024-$8.38M–
Q3 FY2024Sep 30, 2024-$6.85M–
Q2 FY2024Jun 30, 2024-$6.00M–
Q1 FY2024Mar 31, 2024-$7.24M–
Q4 FY2023Dec 31, 2023-$5.46M–
Q3 FY2023Sep 30, 2023-$4.16M–
Q2 FY2023Jun 30, 2023-$3.70M–
Q1 FY2023Mar 31, 2023-$2.71M–
Q4 FY2022Dec 31, 2022-$10.18M-10183.2%
Q3 FY2022Sep 30, 2022-$4.00K–
Q2 FY2022Jun 30, 2022-$5.36M–
Q1 FY2022Mar 31, 2022-$2.99M–
Q4 FY2021Dec 31, 2021$101.00K–
Q3 FY2021Sep 30, 2021-$2.05M–
Q2 FY2021Jun 30, 2021-$910.00K–
Q1 FY2021Mar 31, 2021-$772.00K–
Q4 FY2020Dec 31, 2020-$480.00K–

More Cognition Therapeutics figures

See a number that looks wrong?